Sunshine Biopharma Inc. (NASDAQ: SBFM) closed its public offering on October 9, 2026, securing $6.0 million in upfront gross proceeds. The transaction, conducted on a reasonable best efforts basis, provides immediate capital for general corporate purposes and working capital.

The deal structure includes the potential for an additional $14.4 million in gross proceeds if Series D warrants are fully exercised on a cash basis. This brings the total potential aggregate gross proceeds to approximately $20.4 million. No assurance was provided regarding the exercise of these warrants.

Offering terms and structure

The offering consisted of 10,909,082 Common Units or Pre-Funded Units. Each unit comprised one share of Common Stock or one Pre-Funded Warrant, paired with two Series D Warrants to purchase one share each.

Pre-Funded Warrants are immediately exercisable at $0.00001 per share until exercised in full. Series D Warrants are also immediately exercisable but subject to adjustment as detailed in the final prospectus filed with the SEC.

Use of proceeds and advisory roles

Net proceeds will support general corporate purposes and working capital needs. Aegis Capital Corp. served as the exclusive placement agent for the transaction. Sichenzia Ross Ference Carmel LLP acted as counsel to Sunshine Biopharma, while Kaufman & Canoles, P.C. represented Aegis Capital Corp.

What the numbers show

The capital raise is heavily weighted toward contingent funding rather than immediate cash infusion. While the upfront gross proceeds stand at $6.0 million, the potential additional $14.4 million from warrant exercises represents 70% of the total potential $20.4 million package. This structure indicates that a significant portion of the company's anticipated capital access is dependent on future stock performance exceeding the $0.66 exercise price, rather than being secured at closing.

Company profile

Sunshine Biopharma markets 61 generic prescription drugs in Canada and plans approximately 11 additional launches for the remainder of 2026. The company is advancing two proprietary drug development programs:

• K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.
• PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections.

A registration statement on Form S-1 (No. 333-299274) was declared effective by the SEC on October 7, 2026. The offering was made solely by means of a prospectus.

Shareholders of Sunshine Biopharma have approved an amendment to the company's articles of incorporation to permit a reverse stock split of up to 1-for-20. The move, consented to by the CEO holding approximately 97% of voting power, grants the Board of Directors full discretion over whether to effect the split and the specific ratio within the approved limit.

Shareholder Consent and Voting Power

On September 15, 2026, the company received written consent in lieu of a formal meeting from Dr. Steve N. Slilaty, Chief Executive Officer. Slilaty holds approximately 97% of the total voting power among stockholders. This significant concentration of voting rights allowed for the swift approval of the amendment without convening a general meeting.

The approved amendment authorizes the Board to execute a reverse split of common stock at any whole-number ratio up to 1-for-20. The decision to proceed with the split, as well as the determination of the exact ratio, remains entirely within the Board's discretion.

What the Numbers Show

The approval relies heavily on the CEO's dominant stake. With Dr. Steve N. Slilaty controlling 97% of the voting power, the outcome was effectively predetermined by his written consent. This high level of insider control means that minority shareholder sentiment has negligible impact on this specific corporate action, highlighting a governance structure where major strategic decisions can be executed unilaterally by the primary holder.